Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127129452 | 12712945 | 2 | F | 20160819 | 20160926 | 20160902 | 20160928 | PER | US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-54892BP | BOEHRINGER INGELHEIM | 68.81 | YR | F | Y | 248.00000 | KG | 20160928 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127129452 | 12712945 | 1 | PS | ZANTAC | RANITIDINE HYDROCHLORIDE | 1 | Oral | 150 MG | Y | 560605 | 21698 | 150 | MG | TABLET | QD | ||||
127129452 | 12712945 | 2 | SS | ZANTAC | RANITIDINE HYDROCHLORIDE | 1 | Unknown | Y | 560605 | 21698 | 150 | MG | |||||||
127129452 | 12712945 | 3 | SS | ZANTAC | RANITIDINE HYDROCHLORIDE | 1 | Y | 560605 | 21698 | ||||||||||
127129452 | 12712945 | 4 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 81 MG | 0 | 81 | MG | TABLET | QD | ||||||
127129452 | 12712945 | 5 | C | GLUCOSAMINE | GLUCOSAMINE | 1 | Oral | DS; DOSE PER APPLICATION: 1500 MG; DAILY DOSE: 3000 MG | 0 | CAPSULE | BID | ||||||||
127129452 | 12712945 | 6 | C | AMLODIPINE/BENAZEPRIL | AMLODIPINE BESYLATEBENAZEPRIL HYDROCHLORIDE | 1 | Oral | DOSE PER APPLICATION: 5 MG / 25 MG; DAILY DOSE: 10 MG/ 50 MG | 0 | CAPSULE | BID | ||||||||
127129452 | 12712945 | 7 | C | CARVEDILOL. | CARVEDILOL | 1 | Oral | 12.5 MG | 0 | 6.25 | MG | TABLET | BID | ||||||
127129452 | 12712945 | 8 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | Oral | 12.5 MG | 0 | 12.5 | MG | TABLET | QD | ||||||
127129452 | 12712945 | 9 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 40 MG | 0 | 40 | MG | TABLET | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127129452 | 12712945 | 1 | Bronchitis |
127129452 | 12712945 | 2 | Gastrooesophageal reflux disease |
127129452 | 12712945 | 3 | Reflux laryngitis |
127129452 | 12712945 | 4 | Product used for unknown indication |
127129452 | 12712945 | 5 | Product used for unknown indication |
127129452 | 12712945 | 6 | Hypertension |
127129452 | 12712945 | 7 | Hypertension |
127129452 | 12712945 | 8 | Hypertension |
127129452 | 12712945 | 9 | Product used for unknown indication |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127129452 | 12712945 | Abdominal discomfort | |
127129452 | 12712945 | Abdominal pain upper | |
127129452 | 12712945 | Chest discomfort | |
127129452 | 12712945 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
127129452 | 12712945 | 1 | 20160819 | 0 | ||
127129452 | 12712945 | 2 | 20160817 | 20160822 | 0 |